Condition
Aicardi Goutieres Syndrome
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results67% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Completed2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03921554Phase 2CompletedPrimary
JAK Inhibitor Treatment in AGS
NCT02699190Completed
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
NCT03047369Recruiting
The Myelin Disorders Biorepository Project
NCT04517253Phase 2Terminated
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
Showing all 4 trials